Inherited thrombophilia is significantly associated with severe preeclampsia

Abstract

Methods to prevent the development of pathologies due to placental dysfunctions, such as gestational hypertension and preeclampsia, are the main approaches for obtaining the best maternal and fetal antepartum and postpartum prognosis. During 5 years of study (January, 2015 to December, 2019, the cases of pregnancy and puerperium complicated with pathology due to placental dysfunction were analyzed. The main objective was to determine the magnitude of the impact of thrombophilia on the development of an entity of gestational hypertension disorder. We compared the impact of thrombophilia and its associated complications in patients with gestational hypertension with moderate and severe preeclampsia. Thus, we found obesity, thrombophilia, and underlying cardiac pathology to be significant risk factors for severe preeclampsia. Regarding the comparative analysis of the risk factors and complications associated with patients with mild preeclampsia compared with those with severe preeclampsia, the presence in severe preeclampsia of thrombophilia, endocrine, liver, and cardiac pathology was higher and, a higher rate of complications was observed; complications included fetal death, intrauterine growth restriction (IUGR), prematurity, fetal arrhythmia with acute fetal distress, HELLP syndrome, and placental abruption. Thrombophilia has a significant effect on the development of severe preeclampsia, and oligohydramnios as specific complication of mild preeclampsia. Factors indicating an increased risk of progression from mild preeclampsia to severe preeclampsia are in addition to inherited thrombophilia the underlying pathologies, namely cardiac, hepatic, and endocrine factors.

Polycythemia vera in pregnancy represents a challenge for a multidisciplinary collaboration: A case report and literature review

“…As regards the administration of LMWH, it is not prophylactically recommended for women without active thrombosis or a history of a major thrombotic event (20,29,30). For the case in the present study, the use of a 150 mg daily dose of aspirin was considered, based on the authors' experience in screening and preventing, first and foremost preeclampsia, but also other fetal and maternal complications and the associated risks of intrauterine growth restriction, premature rupture of membranes, abruptio placentae and intrauterine fetal death (32,33). The justification in adding enoxaparin to the treatment of the patient was the existence of associated pathologies: Peripheral venous insufficiency with a high risk of thrombosis in the context of pregnancy and thrombocytosis, as well as an advanced maternal age.…”

The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term

“… 2 Thrombophilia is a group of genetic disorders that cause the blood to clot abnormally and is linked to adverse pregnancy outcomes. 3 , 4 , 5 Therefore, antithrombotic treatment in pregnant patients with previous adverse fetal outcomes, and especially thrombophilia, is recommended. 6 …”

“…The pregnancy‐induced shift in coagulation, as an adaptation to prevent postpartum bleeding, can be abnormally exaggerated in women with thrombophilia, 1 especially after cesarean section, which doubles the risk of thrombotic events compared with vaginal deliveries 2 . Thrombophilia is a group of genetic disorders that cause the blood to clot abnormally and is linked to adverse pregnancy outcomes 3–5 . Therefore, antithrombotic treatment in pregnant patients with previous adverse fetal outcomes, and especially thrombophilia, is recommended 6 …”

“…2 Thrombophilia is a group of genetic disorders that cause the blood to clot abnormally and is linked to adverse pregnancy outcomes. [3][4][5] Therefore, antithrombotic treatment in pregnant patients with previous adverse fetal outcomes, and especially thrombophilia, is recommended. 6 Recurrent pregnancy loss is generated mainly by acquired thrombophilia (antiphospholipid antibody syndrome), according to Alecsandru, 7 while, according to Gandone, 8 inherited thrombophilia (factor V Leiden) is mostly involved.…”

Serum vitamin D3 levels in pregnant women with preeclampsia at third trimester of pregnancy

“…1,4 The risk factors include previous PE, chronic renal disease, chronic hypertension, diabetes mellitus, systemic lupus erythematosus or antiphospholipid syndrome, first pregnancy, maternal age >35 years, body mass index >35 kg/m 2 , inter-pregnancy interval >10 years, family history of PE. 5 The prominent role of vitamin D3, a hormone, in bone homeostasis was firstly reported in the early decades of the 20 th century the discovery that rickets might be prevented and treated by sun exposure. It led to isolation and identification of vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol), then the knowledge about vitamin D role as immunomodulatory, anti-inflammatory, anti-fibrotic, and antioxidant was grew.…”